AbbVie Stock News

AbbVie's strength lies in its ability to innovate. Visa's success is tied to an ongoing long-term trend.

NORTH CHICAGO, Ill. , June 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purchase

The Investment Committee share their top stocks to watch for the second half.

AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.

With the markets trading at all-time highs, it's natural to want to protect your gains by turning to a more defensive strategy. As we've seen throughout history, when the markets go up, they tend to p

NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV

U.S. drugmaker AbbVie will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the companies

-   Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. and BEIJING , June 13, 2024 /PRNewswir

AbbVie, Inc. (NYSE:ABBV ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercia

When it comes to targeting discounted ideas in the equities sector, undervalued blue-chip stocks offer some of the most compelling prospects. First and foremost, blue chips earn the status through dec

Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments. Despite enthusia

NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV

For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence Gap IRVINE, Calif. , June 11, 2024 /PRNewswi